IRIS
Trial Details
- Trial statusAnalysis
- Study email contactiris-trial@imperial.ac.uk
- Chief InvestigatorCarlo Palmieri
- SponsorImperial College London
- PhaseII
A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patient
Design and Objective
Primary Objective: To assess the efficacy of Irosustat when added to existing aromatase inhibitor (AI) therapy in patients who have progressed on an AI based on clinical benefit rate (CBR).
Key inclusion criteria
Written informed consent prior to admission to this study Aged ≥ 25 years of age Histologically confirmed ER+ve primary or metastatic breast cancer according to local criteria Locally advanced or metastatic breast cancer treated with 1st line AI treatment Postmenopausal ECOG performance status 0 to 2 Life expectancy of ≥ 3 months